このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Ekso Bionics Holdings 将来の成長

Future 基準チェック /56

Ekso Bionics Holdingsは、71.2%と24.1%でそれぞれ年率71.2%で利益と収益が成長すると予測される一方、EPSはgrowで72.7%年率。

主要情報

71.2%

収益成長率

72.7%

EPS成長率

Medical Equipment 収益成長	17.6%
収益成長率	24.1%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	30 Jul 2024

今後の成長に関する最新情報

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

May 02

Recent updates

Investors Give Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Shares A 26% Hiding

Aug 29

Many Still Looking Away From Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Jul 13

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

May 02

Market Still Lacking Some Conviction On Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Dec 20

Shareholders May Not Be So Generous With Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO) CEO Compensation And Here's Why

Jun 04

Is Ekso Bionics Holdings (NASDAQ:EKSO) Weighed On By Its Debt Load?

May 26

業績と収益の成長予測

NasdaqCM:EKSO - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	35	1	N/A	N/A	1
12/31/2025	28	-4	N/A	N/A	2
12/31/2024	20	-9	N/A	N/A	2
6/30/2024	18	-12	-11	-11	N/A
3/31/2024	18	-14	-11	-11	N/A
12/31/2023	18	-15	-12	-12	N/A
9/30/2023	17	-15	-14	-14	N/A
6/30/2023	16	-16	-14	-13	N/A
3/31/2023	14	-15	-15	-15	N/A
12/31/2022	13	-15	-15	-15	N/A
9/30/2022	13	-15	-14	-14	N/A
6/30/2022	13	-12	-14	-14	N/A
3/31/2022	12	-11	-13	-13	N/A
12/31/2021	11	-10	-11	-11	N/A
9/30/2021	9	-11	-10	-10	N/A
6/30/2021	9	-6	-9	-9	N/A
3/31/2021	9	-17	-9	-9	N/A
12/31/2020	9	-16	-9	-9	N/A
9/30/2020	10	-15	-9	-9	N/A
6/30/2020	11	-17	-12	-12	N/A
3/31/2020	12	-8	-12	-12	N/A
12/31/2019	14	-12	-16	-16	N/A
9/30/2019	13	-14	-20	-19	N/A
6/30/2019	13	-21	-19	-19	N/A
3/31/2019	12	-26	-21	-21	N/A
12/31/2018	11	-27	-22	-22	N/A
9/30/2018	10	-32	-23	-23	N/A
6/30/2018	10	-31	-27	-27	N/A
3/31/2018	8	-29	N/A	-31	N/A
12/31/2017	7	-29	N/A	-31	N/A
9/30/2017	7	-26	N/A	-30	N/A
6/30/2017	7	-31	N/A	-28	N/A
3/31/2017	7	-35	N/A	-25	N/A
12/31/2016	14	-34	N/A	-25	N/A
9/30/2016	14	-38	N/A	-26	N/A
6/30/2016	15	-31	N/A	-24	N/A
3/31/2016	15	-27	N/A	-21	N/A
12/31/2015	9	-24	N/A	-18	N/A
9/30/2015	8	-35	N/A	-16	N/A
6/30/2015	7	-18	N/A	-15	N/A
3/31/2015	6	44	N/A	-13	N/A
12/31/2014	5	-34	N/A	-15	N/A
9/30/2014	5	-16	N/A	-15	N/A
6/30/2014	4	-30	N/A	-12	N/A
3/31/2014	4	-90	N/A	-12	N/A
12/31/2013	3	-12	N/A	-9	N/A

アナリストによる今後の成長予測

収入対貯蓄率: EKSOは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.5% ) よりも高い成長率であると考えられます。

収益対市場: EKSO今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: EKSO今後 3 年以内に収益を上げることが予想されます。

収益対市場: EKSOの収益 ( 24.1% ) US市場 ( 8.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: EKSOの収益 ( 24.1% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: EKSOの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Ekso Bionics Holdings 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Forecast to breakeven in 2026

Consensus EPS estimates upgraded to US$0.43 loss, revenue downgraded

Price target increased by 8.1% to US$10.00

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

Forecast to breakeven in 2026

Consensus EPS estimates fall by 145%

Recent updates

New major risk - Shareholder dilution

Ekso Bionics Holdings, Inc. has completed a Composite Units Offering in the amount of $5.9971 million.

Ekso Bionics Holdings, Inc. has completed a Composite Units Offering in the amount of $6 million.

Investors Give Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Shares A 26% Hiding

New major risk - Financial position

Forecast to breakeven in 2026

Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Ekso Bionics Holdings, Inc. to Report Q2, 2024 Results on Jul 29, 2024

Many Still Looking Away From Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Ekso Bionics Holdings, Inc. Appoints Deborah Lafer Scher to its Board of Directors

Consensus EPS estimates upgraded to US$0.43 loss, revenue downgraded

Price target increased by 8.1% to US$10.00

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

Forecast to breakeven in 2026

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 06, 2024

Ekso Bionics Holdings, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Consensus EPS estimates fall by 145%

Price target decreased by 7.5% to US$9.25

No longer forecast to breakeven

Full year 2023 earnings: EPS misses analyst expectations

Ekso Bionics Holdings, Inc. to Report Q4, 2023 Results on Mar 04, 2024

Consensus estimates of losses per share improve by 26%

Forecast to breakeven in 2026

Ekso Bionics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. Launches GaitCoach Software for EksoNR

Ekso Bionics Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023

Market Still Lacking Some Conviction On Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Ekso Bionics Holdings, Inc. Receives CMS Coding Approval for Ekso Indego Personal

New major risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ekso Bionics Holdings, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Ekso Bionics Holdings, Inc. Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates increase by 12%, EPS downgraded

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ekso Bionics Holdings, Inc. to Report Q2, 2023 Results on Jul 27, 2023

New minor risk - Share price stability

Sentiment Still Eluding Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Executive Chairman of the Board recently sold US$66k worth of stock

Consensus EPS estimates fall by 40%

High number of new and inexperienced directors

No longer forecast to breakeven

Full year 2022 earnings released: US$1.16 loss per share (vs US$0.80 loss in FY 2021)

Forecast to breakeven in 2025

Ekso Bionics Holdings, Inc Announces Director Changes

Ekso Bionics Holdings, Inc. acquired Human Motion and Control Business Unit of Parker Hannifin Corporation for $10 million.

Price target decreased to US$9.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Ekso Bionics Holdings, Inc. Approves Appointment of Jerome Wong as Corporate Secretary and Principal Financial Officer

Ekso Bionics Holdings, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Ekso Bionics: Fragile Opportunity

Second quarter 2022 earnings: EPS exceeds analyst expectations

Ekso Bionics Holdings, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Is Ekso Bionics Holdings (NASDAQ:EKSO) A Risky Investment?

Ekso Bionics Holdings, Inc. Receives FDA Clearance to Market Its Eksonr(Tm) Robotic Exoskeleton for Use with Multiple Sclerosis Patients

Ekso Bionics Holdings, Inc. Announces Chief Financial Officer Changes

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 09, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$11.00

Ekso Bionics Holdings, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Ekso Bionics Holdings, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Health Check: How Prudently Does Ekso Bionics Holdings (NASDAQ:EKSO) Use Debt?

Ekso Bionics: Expecting More Of The Same